Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1977 2
1981 1
1996 4
1999 2
2001 2
2002 4
2003 5
2004 3
2005 1
2006 1
2007 4
2009 2
2010 2
2011 2
2012 4
2013 1
2014 1
2015 4
2016 2
2017 1
2018 1
2020 9
2021 21
2022 21
2023 30
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Dizman N, et al. Among authors: meza l. Nat Med. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228755 Free PMC article. Clinical Trial.
Cytoreductive Nephrectomy in 2021: Obsolete.
Meza L, Chawla NS, Giannarini G, Pal SK. Meza L, et al. Eur Urol Open Sci. 2021 Dec 29;36:44-46. doi: 10.1016/j.euros.2021.09.021. eCollection 2022 Feb. Eur Urol Open Sci. 2021. PMID: 34988492 Free PMC article. No abstract available.
Nanolattices: An Emerging Class of Mechanical Metamaterials.
Bauer J, Meza LR, Schaedler TA, Schwaiger R, Zheng X, Valdevit L. Bauer J, et al. Among authors: meza lr. Adv Mater. 2017 Oct;29(40). doi: 10.1002/adma.201701850. Epub 2017 Sep 5. Adv Mater. 2017. PMID: 28873250 Review.
Nanofibril-mediated fracture resistance of bone.
Tertuliano OA, Edwards BW, Meza LR, Deshpande VS, Greer JR. Tertuliano OA, et al. Among authors: meza lr. Bioinspir Biomim. 2021 Apr 5;16(3). doi: 10.1088/1748-3190/abdd9d. Bioinspir Biomim. 2021. PMID: 33470971
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
120 results